Shingrix (Zostavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Leading Companies, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Shingrix (Zostavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Leading Companies, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Shingrix (Zostavax) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

The Shingrix (Zostavax) market is experiencing robust growth due to various factors, both historically and in forecast projections. Historically, the growth was fueled by increased awareness of shingles complications, aging global populations, and advancements in immunization guidelines for older adults. The previous limitations of live attenuated vaccines also played a role, alongside rising physician recommendation rates.

Looking forward, the market expansion is driven by increasing adult vaccination coverage targets, heightened healthcare spending on preventive care, and the proliferation of recombinant vaccine pipelines. Government-backed immunization initiatives are gaining momentum, aiming to curb the burden of post-herpetic neuralgia. Industry trends indicate a rising focus on adult immunization programs and an increased demand for long-lasting shingles protection. Furthermore, advancements in cold-chain optimized vaccine distribution and a strong emphasis on vaccine safety and efficacy underscore this growth trajectory.

The uptake of innovative vaccination solutions is anticipated to propel the Shingrix market forward. Public health campaigns and enhanced healthcare infrastructure play a vital role in the widespread acceptance of vaccines. Shingrix (Zostavax) is pivotal in this context, providing high-efficacy protection against shingles, significantly mitigating the risk of recurrence and complications such as post-herpetic neuralgia. A notable study published in May 2024 by the Journal of the American Medical Association revealed a 46% increase in shingles vaccinations covered by Medicare Part D, post-IRA policy implementation in January 2023.

Major industry players, such as GSK plc, are focusing on developing non-live, recombinant subunit adjuvanted vaccines to meet the growing demand for safer and more effective immunization, particularly among aging and immunocompromised populations. GSK's 2023 launch of Shingrix in India, a vaccine with a robust immune response and high efficacy, highlights this innovation focus.

Strategic partnerships are expanding market reach, as exemplified by GSK's collaboration with Chongqing Zhifei in October 2023 to enhance Shingrix distribution in China. North America remains the largest regional market, with Asia-Pacific anticipated as the fastest-growing region. Tariffs impact vaccine production and distribution costs, pressing for cost-effective strategies and regional manufacturing resilience, particularly affecting North America and Europe.

The comprehensive market analysis encompasses statistics on market size, regional shares, competitor analysis, and emerging trends, offering crucial insights. Shingrix and Zostavax formulations vary from recombinant vaccines to live-attenuated options, distributed through hospital and retail pharmacies. The market's financial realm is captured through 'factory gate' values, signifying direct manufacturer sales to various market entities.

Key Topics Covered:

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Shingrix (Zostavax) Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Shingrix (Zostavax) Market Attractiveness Scoring and Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment and Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Shingrix (Zostavax) Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List of Key Raw Materials, Resources & Suppliers

3.3. List of Major Distributors and Channel Partners

3.4. List of Major End Users

4. Global Shingrix (Zostavax) Market Trends and Strategies

4.1. Key Technologies & Future Trends

4.1.1. Biotechnology, Genomics & Precision Medicine

4.1.2. Industry 4.0 & Intelligent Manufacturing

4.1.3. Digitalization, Cloud, Big Data & Cybersecurity

4.1.4. Sustainability, Climate Tech & Circular Economy

4.1.5. Internet of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1. Increasing Adoption of Recombinant Vaccine Platforms

4.2.2. Rising Focus on Adult Immunization Programs

4.2.3. Growing Demand for Long-Lasting Shingles Protection

4.2.4. Expansion of Cold-Chain Optimized Vaccine Distribution

4.2.5. Enhanced Emphasis on Vaccine Safety and Efficacy

5. Shingrix (Zostavax) Market Analysis of End Use Industries

5.1. Hospitals

5.2. Specialty Clinics

5.3. Immunization Centers

5.4. Retail Pharmacies

5.5. Public Health Organizations

6. Shingrix (Zostavax) Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market

7. Global Shingrix (Zostavax) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis

7.1. Global Shingrix (Zostavax) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Shingrix (Zostavax) Market Size, Comparisons and Growth Rate Analysis

7.3. Global Shingrix (Zostavax) Historic Market Size and Growth, 2020-2025, Value ($ Billion)

7.4. Global Shingrix (Zostavax) Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)

8. Global Shingrix (Zostavax) Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Shingrix (Zostavax) Market Segmentation

9.1. Global Shingrix (Zostavax) Market, Segmentation by Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)

9.2. Global Shingrix (Zostavax) Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Shingles Prevention, Post-Herpetic Neuralgia

9.3. Global Shingrix (Zostavax) Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy

10. Shingrix (Zostavax) Market Regional and Country Analysis

10.1. Global Shingrix (Zostavax) Market, Split by Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Shingrix (Zostavax) Market, Split by Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/o499y4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.